Recall Record

Monmouth Junction, NJ, United States

Tris Pharma Inc. recalls

3 recalls recorded since 2018, most recently on 11 July 2019. None are listed as ongoing. Status and classification are as published by the FDA.

Recalls3
Ongoing (FDA)0
Terminated or completed3
Class I (FDA)0

Terminated Class II Drugs

Recall started
11 July 2019
Terminated
2 November 2021
Reason
Superpotent Drug and Failed Stability Specifications: High out-of-specification results for the active ingredients, hydrocodone and chlorpheniramine, as well as high out-of-specification results for the preservatives.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1517-2019

Terminated Class II Drugs

Recall started
15 January 2019
Terminated
29 March 2023
Reason
Superpotent Drug: recalled lots may have higher concentration of ibuprofen than amount labeled.
Distribution
One distributor who further distributed Nationwide in the USA.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0494-2019, D-0495-2019, D-0493-2019

Terminated Class II Drugs

Recall started
26 November 2018
Terminated
1 April 2021
Reason
Superpotent Drug: recalled lots may have higher concentration of ibuprofen.
Distribution
One distributor in PA who further distributed Nationwide in the USA.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0335-2019, D-0336-2019, D-0337-2019

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.